Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MÁ, Liria MR, Pérez-Alcántara F. Alba E, et al. Among authors: perez alcantara f. Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):381-91. doi: 10.1586/erp.13.18. Epub 2013 Mar 28. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23534988 Clinical Trial.
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Carrato A, García P, López R, Macarulla T, Rivera F, Sastre J, Gostkorzewicz J, Benedit P, Pérez-Alcántara F. Carrato A, et al. Among authors: perez alcantara f. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):579-89. doi: 10.1586/14737167.2015.1047349. Epub 2015 May 19. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25991037
Estimate of the cost of multiple sclerosis in Spain by literature review.
Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F. Fernández O, et al. Among authors: perez alcantara f. Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 28726515 Review.
Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?
Lekuona I, Anguita M, Zamorano JL, Rodríguez JM, Barja de Soroa P, Pérez-Alcántara F. Lekuona I, et al. Among authors: perez alcantara f. Rev Esp Cardiol (Engl Ed). 2019 May;72(5):398-406. doi: 10.1016/j.rec.2018.03.024. Epub 2018 Jul 7. Rev Esp Cardiol (Engl Ed). 2019. PMID: 31007166 English, Spanish.